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1. Introduction
Mass spectrometry (MS) has become a powerful analytical tool for qualitative and quantita‐
tive applications, providing information about the structure and purity of compounds, and
also about the chemical composition of complex samples.
The most recent applications of mass spectrometry are oriented towards biochemical appli‐
cations such as proteome, metabolome and drug discovery. During the last decade, mass
spectrometry has progressed rapidly and an evolution has been observed in the type of ap‐
plications, software and equipments. Atmospheric pressure ionization sources are now
used, an analyser based on a new concept (the orbitrap) was recently developed, existing
ones were modified, and new hybrid instruments were developed using combinations of
different analysers, depending on applications. One of the major trends was the transition to
high resolution/accurate mass analysis, made routine by new MS instruments. The use of
separation techniques as gas chromatography (GC), liquid chromatography (LC) and capil‐
lary electrophoresis (CE) coupled with mass spectrometry and tandem mass spectrometry,
expanded the interest in this methodology.
In this chapter are presented general aspects related with characteristics of mass spectrome‐
try equipments. The contribution of this technique to new discoveries concerning one of the
major infectious diseases in man, malaria, is also discussed.
2. Basics of mass spectrometry
Mass spectrometry is a technique used to analyse from small inorganic molecules to biologi‐
cal macromolecules and relies on the formation of gas-phase ions (positively or negatively
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charged) that are isolated based on their mass-to–charge ratio (m/z). In order to achieve this
state, the sample must be volatilized and this may become a problem to biological samples,
as biomolecules have usually high molecular mass and high polarity, factors that limit their
volatility.
All mass spectrometers share common components as an ionization source, a mass analyser
and a detector (Fig. 1). As there are available equipments with different specifications, even
from the same supplier, it is necessary to choose carefully the most adequate equipment for
each type of application.
Figure 1. Basic components in a mass spectrometer. ESI, electrospray ionization, APCI, atmospheric-pressure chemical
ionization; MALDI, Matrix-Assisted Laser Desorption ionization; DESI: Desorption Electrospray Ionization ; DART: Direct
Analysis in Real Time; FT-ICR: Fourier transform ion cyclotron resonance (adapted from Glish & Vachet, 2003)
In order to achieve this state, the sample must be volatilized and this may become a problem
to biological samples, as biomolecules have usually high molecular mass and high polarity,
factors that limit their volatility.
Different ionization techniques may be used in mass spectrometry equipments, depending on
the need of molecule disruption for the induction of ion formation. These techniques may
perform strong and soft ionization processes. Soft ionization methods, like fast atomic
bombardment (FAB), liquid secondary ion mass spectrometry (LSIMS), matrix-assisted laser
desorption ionization (MALDI) and electrospray ionization (ESI) allow the detection of
molecular ions and are more suitable for the analysis of biomolecules and non-purified
analytes. The ions are generated by protonation, deprotonation or formation of adducts. In
table 1 are summarized some of the main characteristics of the most used ionization methods.
The use of FAB is useful to assign the molecular ion peaks. The sample is dissolved in a suitable
liquid matrix, with low vapour pressure (e.g. diethanolamine, triethanolamine, glycerol,
thioglycerol or 3-nitrobenzyl alcohol), inserted into the mass spectrometer and bombarded
with high energy argon or xenon atoms, providing efficient means to analyze polar, ionic,
thermally labile, energetically labile, and high molecular mass compounds (El-Aneed et al.,
2009).
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In MALDI, ions are produced by pulsed-laser irradiation (e.g. nitrogen lasers) of the sample
co-crystallized with an organic matrix (e.g. gentisic, sinapic or ferulic acid) and operating in
the vacuum or more recently, at atmospheric pressure. MALDI ionization uses a low amount
of sample but low molecular mass molecules (below 500 Da) are difficult to analyse, due to
strong interferences of the organic matrix ions.
The development of other soft ionization techniques has become crucial to the analysis of
biomolecules dissolved in a mixture of water and a volatile organic solvent (e.g. methanol,
acetonitrile). Techniques as ESI and MALDI make MS methodologies versatile as both
techniques accomplish the conversion into gas-phase ions of non-volatile and thermally labile
large molecules, allowing the study of biological compounds. Both techniques produce
protonated peptide and protein ions, deprotonated deoxyribonucleic acids (DNA) and
ribonucleic acids (RNA). Some reviews have been published on the covalent and non-
convalent interactions between drug molecules with DNA and RNA, protein and enzyme
targets for drug action and toxicity (Feng, 2004). When using ESI, proteins are ionized as they
have several sites of protonation or deprotonation, and this multiple charging enables mass
spectrometers with limited m/z ranges to analyse higher molecular mass molecules. However,
ion suppression may occur when solutions contain high concentrations of salt, or when the
target analytes are present in low concentration in matrices with high content of other analytes.
Strategies based on the type of analyte, ionization reaction, ionization efficiency, analyte
solution composition and pH, have been described for producing positive or negative ion
modes when operating with an ESI source (Feng, 2004). APCI, is less susceptible to matrix
interferences from salts, and is used for monitoring weakly polar compounds. However, labile
Ionization
method Analytes Sample introduction Mass range Type of ionization
FAB Organometalliccompounds Direct injection, LC <5000 Da Soft
MALDI Biomolecules Sample co-crystallizedwith a matrix 500-500 000 Da
Very soft. Generates mainly
single charged ions
ESI Organic and inorganiccompounds Direct injection, LC Large range
Softer than MALDI.
Generates multiple charged
ions
DESI
Small non-polar and
large polar molecules
(peptides and proteins)
Analysis of a surface Large range
Generates single or
multiple charged molecular
ions from small or large
analytes
DART Low molecular masscompounds Analysis of a surface Less broad than DESI
Simple mass spectra
(molecular ion)
Table 1. Characteristics of the most used ionization sources. FAB: Fast Atomic Bombardment; MALDI: Matrix Assisted
Laser Desorption Ionization; ESI: Electrospray Ionization; DESI: Desorption Electrospray Ionization ; DART: Direct
Analysis in Real Time
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compounds can be thermally decomposed, and due to its high sensitivity, the solvents used
with this technique must have higher purity.
DART and DESI are well established open-air ionization techniques, as no sample preparation
is required, making these techniques suitable for screening a large number of samples
(Fernández et al., 2006). The DART ion source produces a heated stream of protonated reactant
ions and the analytes in the sample are ionized, producing protonated molecules [M+H]+ or
deprotonated molecules [M-H]-in the open air of the laboratory environment, making possible
the analysis of organic compounds directly, in real time, without time-consuming analytical
protocols and destruction of the sample. The method may detect concentrations of analytes as
low as femtomole (Arnaud, 2007). Due to these characteristics, DART has become an ionization
method useful for rapid screening of pharmaceutical products. In DESI analysis, a high-speed
charged liquid spray is directed to the sample (Takats et al., 2005). The DESI spray dissolves
the material from the sample and the charged droplets are sampled downstream by a mass
spectrometer. Desolvation and evaporation from these droplets creates ions that will generate
a mass spectrum of the sample components.
Following the ionization process, the selected ions are extracted, accelerated, and analyzed. A
mass analyser is characterized by its mass range limit, analysis speed, transmission, mass
accuracy and resolution, expressed as full width at half maximum (FWHM). The most used
analysers and their characteristics are summarized in Table 2.
Quadrupoles are widely used mass analysers, where ions are separated according to the
stability of their trajectories in the oscillating electric fields applied between the four parallel
rods. The QTOF, a hybrid quadrupole time of flight mass spectrometer, is a high-resolution
mass spectrometer with MS/MS capability, and has been often used in drug studies (Nyunt et
al., 2005). FT-ICR is also a high resolution and high mass accuracy analyser that enables the
study of the binding of ligands (drugs) to RNA targets (Hofstadler et al., 1999; Masselon et al.,
2000). The Orbitrap mass analyzer employs electrostatic trapping and it bears similarities to
FT-ICR as both belong to the same Fourier Transform MS (FTMS) family of instruments.
Orbitrap mass spectrometry is expected to provide maximum resolving powers of 100,000–
200,000. A modified Orbitrap instrument has shown that this technology is capable of a
resolution of 1,000,000 for m/z < 300–400, which makes it compatible to be used with chroma‐
tographic separation techniques (Denisov et al., 2012).
Tandem mass spectrometry (MSn) development was crucial for the structural analysis of
compounds. In tandem experiments, a molecular ion is selectively isolated and fragmented in
a controlled environment. With this type of analysers, it is possible to perform different types
of experiments (e.g. parent scan, daughter scan, neutral loss) and data obtained, will allow to
identify or quantify the analytes, even in complex matrices (e.g. natural product extracts and
biological fluids). Multiple Reaction Monitoring (MRM), has become an important tool, used
for quantification purposes, allowing an increment of methods specificity and sensitivity.
Finally the signal obtained in the detector will produce a mass spectrum, the x-coordinate
represents m/z values and the y-axis indicates total ion counts.
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Liquid chromatography coupled to mass spectrometry (Triple Quadrupole TQ, QTOF, Linear
ionTrap and Linear QTRAP analyzers) is today a well established methodology used due to
its high sensitivity, speed, selectivity, versatility and ease of automation. Recently the advan‐
tages of using mass spectrometry in comprehensive liquid chromatography (LC X LC system)
have been discussed and different applications have been described for pharmaceutical
compounds (Donato et al., 2012).
3. An overview of malaria
Malaria is caused by Plasmodium parasites, which are transmitted through the bite of an
infected female Anopheles mosquito, and remains one of the major infectious disease in man.
Five species from the genus Plasmodium namely: P. falciparum, P. vivax P. ovale, P. malariae, and
P. knowlesi cause infection in humans. Of these, P. falciparum and P. vivax account for more than
95% of malaria cases in the world, with P. falciparum, being responsible for most of the deaths
caused by malaria every year. The species of human malaria differ in the periodicity of their
Quadrupole Ion Trap Time-of-flight
Time-of-flight
reflectron
Magnetic
sector
Fourrier
Transform ion
cyclotron
resonance
Fourrier
Transform
Orbitrap
Symbol Q IT TOF TOF B FT-ICR FT-OT
Principle of
separation
m/z (trajectory
stability)
m/z
(resonance
frequency)
Velocity
(flight
time)
Velocity
(flight time) Momentum
m/z
(resonance
frequency)
m/z
(resonance
frequency)
Mass limit
(Th) 4 000 6 000 >1 000 000 4 000 20 000 30 000 50 000
Resolution
FWHM (m/z
1000)
2 000 4 000 5 000 20 000 100 000 500 000 100 000
Accuracy
(ppm) 100 100 200 10 <10 <5 <5
Ion sampling continuous pulsed pulsed pulsed continuous pulsed pulsed
Pressure
(Torr) 10
-5 10-3 10-6 10-6 10-6 10-10 10-10
Tandem mass
spectro-
metry
MS/MS
Fragments
Precursors
Neutral loss
Low-energy
collision
MSn
Fragments
Low-energy
collision
-------
MS/MS
Fragments
Low-energy
collision
MS/MS
Fragments
Precursors
Neutral loss
High-energy
collision
MSn
Fragments
Low-energy
collision
-------
Table 2. Comparison of mass analysers (adapted from Hoffmann & Stroobant, 2002)
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life cycle, as well as in the outcomes of the disease. Generally clinical manifestations can include
fever, chills, prostration and anemia. Severe disease can include delirium, metabolic acidosis,
cerebral malaria and multi-organ system failure, coma and death may ensue. (Kantele &
Jokiranta, 2011)
The World Health Organization (WHO) estimated 225 million cases of malaria and about
800,000 deaths worldwide in 2010 (WHO, 2010). Due to the rapid evolution and spread of
multi-resistant parasites to the current antimalarial drugs, both, chemotherapy and prophy‐
laxis are at risk of impairment. Malaria is most prevalent in developing countries of tropical
areas such as sub-Saharan Africa, East Asia and South America (Rodrigues et al., 2010;
Eisenstein, 2012).
3.1. Life cycle of the malaria parasite
The malaria parasite exhibits a complex life cycle (Fig. 2) involving an insect vector (mosquito)
and a vertebrate host (human). It includes an asexual cycle in humans, encompassing an
asymptomatic liver-stage, a symptomatic blood-stage and a sexual cycle in a mosquito.
The liver or hepatic stage (A) is initiated when sporozoites injected through the bite of a
mosquito travel to the liver and infect hepatocytes, where a clinically silent asexual multipli‐
cation takes place, generating thousands of merozoites. The release of merozoites into the
bloodstream (B) marks the beginning of the erythrocytic stage of infection (C), during which
parasites infect red blood cells, undergo repeated asexual replication cycles, and give rise to
clinical illness. Some merozoites differentiate into gametocytes (D) that can be taken up by the
mosquito during a posterior blood meal. Within the mosquito, gametocytes undergo a sexual
development to form sporozoites that migrate to the salivary glands and can infect another
host trough another bite (E).
 
A 
B 
C 
D 
E 
Figure 2. Plasmodium life cycle
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3.2. Agents with antimalarial activity
The public health problem of malaria has been addressed by different approaches (Biot et al.,
2012):
• use of insecticides to control the mosquito vector, but mosquitoes are developing resistance
to insecticides;
• vaccines, but in spite of all the efforts there is yet not available a vaccine that effectively
targets the parasite;
• chemotherapy to control malaria has relied mainly on a restricted number of chemically
related drugs belonging to either the quinoline or the antifolate groups.
Increasing resistance of P. falciparum to the commonly used drugs is recognized as one of
the  major  problems  in  eradication  of  the  disease.  The  severe  malaria  situation  under‐
scores  the  continuing need of  research for  new classes  of  antimalarial  agents  with  new
mechanisms of action or re-utilization of the existing drugs with new types of therapies.
The existing drug armamentarium is  insufficient  to  answer the call  for  malaria  eradica‐
tion. The first line of treatment for malaria currently relies on a single class, the artemisi‐
nins.  To  overcome  this  problem  scientists  are  exploring  many  approaches,  targeting
different stages of  the parasite life  cycle,  to find agents that  will  prevent,  cure or elimi‐
nate malaria. (Hobbs, C. & Duffy, P., 2011)
Many  antimalarial  agents  contain  a  4-aminoquinoline,  8-aminoquinoline  or  quinolone
methanol  scaffolds  (Rosenthal,  2001).  Chloroquine  and  amodiaquine  are  4-aminoquino‐
lines used to treat and prevent malaria, while primaquine is the single 8-aminoquinoline
clinically approved to treat relapsing malaria caused by P. vivax.  Mefloquine (Fig. 3) is a
quinoline  methanol  antimalarial  structurally  similar  to  quinine,  the  first  pure  substance
used  to  treat  malaria  and  extracted  from the  bark  of  the  cinchona  tree.  Other  relevant
classes of antimalarial agents include the antifolates (e.g. pyrimethamine and proguanyl),
phenanthrene  methanols  (e.g.  halofantrine),  and  naphthoquinones  (e.g.  atovaquone).
More recently, artemisinin (Fig. 3), a sesquiterpene lactone isolated from the Artemisia an‐
nua chinese herb, and its analogues were a major breakthrough in malaria chemotherapy
because they produce a very rapid therapeutic  response,  particularly against  multidrug-
resistant Plasmodium falciparum malaria.
With exception of  primaquine,  (Vale  et  al.,  2009)  most  available  antimalarials  are  active
against  the  blood  stage  of  the  disease.  However  to  achieve  the  eradication  goal,  new
compounds  with  new  modes  of  action  are  needed  to  block  parasite  transmission  and
eliminate the asymptomatic and latent hepatic forms. (Rodrigues et al.,  2012) A strategy
used to address this major goal is to combine two chemotypes - each one targeting a spe‐
cific stage of the parasite’s life cycle in a single chemical entity, to develop effective hy‐
brid  antimalarials  capable  of  killing  both  the  blood  and  liver-stage  parasites  with
identical efficacy. (Capela et al., 2011)
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4. Study of antimalarials agents by mass spectrometry
Structural and stability information is fundamental for any drug study, including antimalar‐
ials. In fig. 3 are presented currently available antimalarial drugs. Due to the rapid emergence
and spread of resistant parasites to well-established antimalarial drugs, there is an urgent need
for novel drugs. Studies performed on new antimalarial compounds using mass spectrometry
are scarce but are useful for the elucidation of structures, also for prediction of compound
stability and properties, isomer characterization, and detection of counterfeit products.
Furthermore, studies using this technique coupled to chromatographic methods have been
conducted for the evaluation of pharmacokinetics, metabolite identification, and detection of
impurities.
4.1. Structural elucidation
One of the main applications of mass spectrometry is the structural elucidation of molecules.
Based on the molecular ion peaks and their fragmentation patterns, the structure of com‐
pounds can then be proposed.
Among the different equipments that can be used for these purposes, FAB ion sources are
frequently described. Applications can be found in the study of the oxidation products of
primaquine, 5,5-di-[6-methoxy-8-(4-amino-1-butyl amino)] quinoline (PI), 6-methoxy-5,8-di-
[4-amino-1-methyl butyl amino] quinoline (PII) and 5,5-di-[7-hydroxy-6-methoxy-8(4-
amino-1-methyl butylamino)] quinoline (PIII) (Fig. 4) (Sinha & Dua 2004). The mass spectrum
of PI with molecular formula C30H40N6O2 presents the molecular ion at m/z 517 confirming the
molecular mass of the compound, and a fragment at m/z 500 is detected due to the presence
of a terminal amino group at position 4´.
An LC-MS/MS method was developed for the analysis of bulaquine (BQ) 3-[1-[4-[(6-me‐
thoxy-8-quinolinylamino] pentylamino] ethylidene]dihydro-2 (3H)-furanone (Fig. 5) and its
metabolite primaquine in monkey plasma. Protonated species at m/z 370 and 260 were detected
for bulaquine and primaquine, respectively. MS/MS conditions were optimized generating
product ions through fragmentation of the molecular ions. Based on the fragmentation spectra
obtained from [M+H]+ under the established analytical conditions, a fragmentation pattern
was presented for these compounds. This type of study is important to establish analytical
conditions for the quantification of drugs and their metabolites in biological fluids. (Nitin et
al., 2003)
An ESI-Ion trap mass spectrometer was used to perform MSn analyses, in the study of
imidazolidin-4-one peptidomimetic derivatives of primaquine. (Vale et al., 2008a)
4.2. Pharmacokinetic studies
Pharmacokinetic (PK) studies provide a mathematical basis to assess the time course of drug
in the body. It enables to quantify absorption, distribution, metabolism and excretion of the
drug and their metabolites. The primary requirement to undertake a PK study, is to have an
Tandem Mass Spectrometry - Molecular Characterization68
analytical method which is reliable, reproducible, sensitive, selective, and if possible, compat‐
ible with high-throughput pharmacokinetic approaches.
Drug efficacy requires adequate drug concentration at the site of action. Monitoring drugs and
their metabolites in biological samples (in vivo studies), is fundamental in order to control the
intake of the antimalarials by the infected populations. Mass spectrometry has been success‐
fully used for this purposes, coupled with liquid chromatography, and analytical methods
N
HN
Cl
N
N
HN
Cl
OH
N
N
HN
O
NH2
N
HO
HN
CF3
CF3 N
O
N
H
HO
H
Cl
N
N
NH2
H2N
Cl NH
NH
HN
HN
NH
O
O
OH
Cl
O
O
O
H H
H
O O
HO
F3C
Cl
Cl
N
Chloroquine Amodiaquine Primaquine
Mefloquine Quinine Pyrimethamine
Proguanyl
Atovaquone Artemisinin
Halofantrine
Figure 3. Currently available antimalarial drugs
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have been optimized and validated for quantification of different drugs and metabolites in
biological fluids.
A LC-MS/MS method was used to study 14 antimalarial drugs, which are the components of
the current first-line combination treatments for malaria (artemether, artesunate, dihydroar‐
temisinin, amodiaquine, N-desethyl-amodiaquine, lumefantrine, desbutyl-lumefantrine,
piperaquine, pyronaridine, mefloquine, chloroquine, quinine, pyrimethamine and sulfadox‐
ine). The best conditions for mass spectrometry analysis were optimized (Hodel et al., 2009)
and the method developed was implemented, and used to analyse samples from an in vivo
study with 125 Southeast Asian patients from two regions of Cambodia: one region with a
high level of antimalarial drug resistance and another region with moderate levels of drug
resistance (Hodel et al., 2010). The 14 antimalarial drugs were measured in plasma samples
from the patients, and results showed that for half of them, an antimalarial drug was detected
namely mefloquine, piperaquine, chloroquine or quinine. However all patients reported either
not having taken any antimalarial before or not knowing to have taken. These results are
important, as they show that it is urgent to ensure appropriate use of antimalarials among the
populations.
Tafenoquine (8-[(4-amino-1-methylbutyl)amino]-2,6-dimethoxy-4-methyl-5-(3-trifluorometh‐
yl-phenoxy) quinoline succinate) (Fig. 6) was measured in human plasma from patients and
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Figure 4. The oxidative antimalarial primaquine analogous (PI, PII and PIII)
N
O
NH
NH
OO
Figure 5. Bulaquine
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healthy volunteers during a clinical efficacy trial, using a LC-MS/MS equipment.(Doyle et al.,
2002)
N
HN
O
H3CO
NH2
F3C
OCH3 . HO2C CO2H
Figure 6. Tafenoquine
For NPC1161 (Fig. 7), an 8-aminoquinoline analog (8-[(4-amino-1-methylbutyl)amino]-5-[3,4-
dichloro-phenoxyl]-4-methyl-quinoline) and their metabolites, a LC-MS method using an electro‐
spray ionization source and a TOF analyzer, was implemented.
 
Figure 7. NPC1161, an 8-aminoquinoline analog
Using mass spectrometry other antimalarial molecules as α-/β-diastereomers of arteether (AE),
sulphadoxine (SDX) and pyrimethamine (PYR) (Sabarinath et al., 2006) and three novel
trioxane antimalarials (Fig. 8) (Singh et al., 2008) were determined in rat plasma. A N-alkyla‐
midine compound, M64, and its corresponding bioprecursors were measured in human and
rat plasma (Margout et al., 2011) (Fig. 9). Artemisinin class compounds and its active in-vivo
metabolites were analysed in monkey plasma (Singh et al., 2009).
O
OO
O
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O
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Figure 8. Chemical structures of three novel trioxane antimalarials
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A method was also developed and validated according to FDA guidelines for simultaneous
determination of two mono-thiazolium compounds in plasma, whole blood and red blood
cells from human and rat (Taudon et al., 2008). More recently a rapid (3 min analysis) and
sensitive UPLC-MS/MS method using a triple quadrupole tandem mass spectrometer in
positive ESI mode, has been implemented for the analysis of ARB-89 (7α-hydroxy artemisinin
carbamate) (Fig. 10) in rat serum, for pharmacokinetics studies, (Pabbisetty et al., 2012).
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Figure 10. ARB-89 (7α-hydroxy artemisinin carbamate)
Mass spectrometry has proven to be particularly useful in identifying complex metabolites as
those arising from phase I (e.g. those involving cytochrome P450 monooxygenases) and phase
II (e.g. conjugation with glucuronic acid, sulfonates, glutathione or amino acids) reactions. In
a study published by Liu et al., 2011, metabolites of artemisinin, also known as Qing-hao-su
(QHS), and its active derivative dihydroartemisinin (DHA) were identified in in vitro and in
vivo biological samples using a LTQ-Orbitrap mass spectrometer in tandem with H/D ex‐
change. The authors were able to show that artemisinin drugs mainly undergo hydroxylation
and loss of oxygen in the phase I metabolic pathway and can form glucuronides in the phase
II processes, as shown in Fig. 11. Based on MS data it was proposed a metabolic pathway for
these metabolites.
Piperaquine was synthesized for the first time about 50 years ago, but seems to be a suitable
partner drug in artemisinin-based combination treatments. In a paper published by Tarning
et al., 2006, the main metabolites of piperaquine were characterized in a 16-h human urine,
after a single p.o. administration of a fixed combination of dihydroartemisinin-piperaquine,
with a fatty meal. A LC method in tandem with a QTRAP system was used to analyse
piperaquine and its metabolites and a FT-ICR/MS equipment was used to obtain mass spectra
H3C NH
N
H
CH3
NN
XX
12
M64, X=H; M64AH, X=OH; M64-S-Me, X=OSO2CH3
Figure 9. Chemical structures of compound, M64, and its corresponding bioprecursors
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of the five metabolites of piperaquine in urine samples. Two of the metabolites (a carboxylic
and a mono N-oxidated piperaquine metabolite) were considered as the most relevant as they
were detected in the serum/plasma samples collected up to 93 days, and also in urine 123 days
after administration of the drug. Other two monohydroxylated metabolites and a di-N-
oxidized metabolite were also detected in urine samples.
4.3. Detection of impurities
A major impurity (8-(4-amino-4-methylbutylamino)-6 methoxyquinoline) associated with
primaquine drug samples (Fig.12), obtained from European Pharmacopoeia and other
commercial sources, was detected by gas chromatography-electron impact-mass spectrometry
(GC–EI-MS) (Dongre et al., 2005).
4.4. Chemical stability studies
Mass spectrometry can also be conducted in order to contribute to study the properties of
compounds, through knowledge of their stability and fragmentation mechanisms, under the
gas-phase conditions of a mass spectrometer. This type of studies can have, in the future,
important implications in drug analysis and development.
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Studies on primaquine derived imidazolidin-4-ones using an ESI-ion trap mass spectrometer
have allowed to find a correlation between the stability of the ions in the nozzle-skimmer
region during the CID (Collision Induced Dissociation) analyses and reactivity in both isotonic
buffer and human plasma (Vale et al., 2008). The same authors (Vale et al., 2008a) studied
imidazolidin-4-one peptidomimetic derivatives of primaquine, PQAAPro and PQProA (Fig.
13) and they also found the parallelism between compound reactivity to hydrolysis and
stability during CID analysis. Using CID and MS/MS experiments to study the peptidomimetic
imidazolidin-4-one derivatives of primaquine, it was possible to conclude that CID spectra
reflected the reactivity of compounds under physiological conditions, and the relative
abundances of MS/MS generated fragments were correlated with the Charton steric parame‐
ters associated to amino acid side chain in the molecule (Vale et al., 2009).
From the results obtained, ESI-MS proved to be a reliable tool for stability prediction of
compounds towards hydrolysis at physiological pH and temperature although the mecha‐
nisms in water and in the gas-phase are not comparable. This type of studies were, for the first
time, approached by these authors.
 
Figure 12. Fragmentation pattern of primaquine and the corresponding impurity
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Figure 13. PQ imidazolidin-4-ones, PQAAPro and PQProAA mimetic derivatives of primaquine
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4.5. Detection of counterfeit drugs
The quality of commercially available drugs varies among countries. The WHO/International
Medical Products Anti-Counterfeiting Taskforce estimates that in some less developed
countries, the counterfeit drugs are up to 50% of the total drugs supplied to the popula‐
tions(Hall et al., 2006). Due to the lack of regulations and poor quality control practices, the
amount of the active ingredient may be incorrect, as a result of chemical degradation that
occurs due to poor storage conditions, especially in warm and humid tropical environments.
In some cases, expired drugs are repackaged with new expiration dates and put in the market.
Also some drugs can be contaminated or replaced by other substances and people consume
sawdust, paint and other toxic or inert substances (Kaur et al., 2009).
The report published by WHO in 2011, about the quality of antimalarial drugs in 6 countries
of sub-Saharan Africa (Cameroon, Ethiopia, Ghana, Kenya, Nigeria and the United Republic
of Tanzania) resumes the results obtained from the analysis of 935 samples and gives an idea
about the quality and counterfeits that more often occur.
As an incorrect intake can result in a low bioavailability of the drug in the individual, leading
to drug-resistance strains, provoking a therapeutic failure, reliable methods of analysis must
be available to determine the quality of antimalarials commercialized, and LC coupled with
mass spectrometry can be used. However this technique is expensive, requires training,
technological support, and sample preparation. Actually, DART (Fernández et al., 2006) and
DESI (Haiss et al., 2007) methodologies are often used, as they produce results rapidly, because
they do not require sample preparation. Results obtained from a DESI MS method were used
to validate Fourier-transform infrared imaging for characterization of counterfeit antimalarial
pharmaceutical in tablets (Ricci et al., 2007). A DESI MS method was also applied for the
quantitative screening of counterfeit antimalarial tablets containing artesunate (Nyadong et
al., 2008), and more recently DESI and DART methods were used to validate results from the
application of FT-Raman spectroscopy for in situ screening for potentially counterfeit artesu‐
nate antimalarial tablets (Ricci et al., 2008).
4.6. Rapid diagnosis of malaria
The rapid diagnosis of malaria infection can also be performed by mass spectrometry.
Hemozoin, the malaria pigment, can be detected by laser desorption mass spectrometry
(LDMS) in human blood. (Scholl et al., 2004) Detection of malaria in 45 asymptomatic pregnant
Zambian women was performed by this technique. Detection of Plasmodium falciparum malaria
during pregnancy is complicated by sequestration of parasites in the placenta reducing
peripheral blood microscopic detection. LDMS was able to detect <10 parasites/uL cultured in
human blood and provided a more rapid mean of screening for infection than the technique
used currently for this purpose, light microscopy (Nyunt et al., 2005).
5. Conclusions
The information obtained from the use of mass spectrometry in the study of antimalarials
agents is important, in order to understand all the mechanisms of the illness, malaria, and the
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way the different drugs interact in the human organism. Due to its characteristics (sensitivity,
speed, possibility to be automated, possibility to combine with separation techniques) and
diversity of equipments available, mass spectrometry can be used in the structural identifica‐
tion of new molecules, in the study of many phases of drug discovery, for assessment of
compound stability, pharmacokinetic studies monitoring the concentrations of antimalarials
and metabolites in biological matrices, the studies of cell permeability and plasma protein
binding, and finally, in the quality control of commercial drugs.
The use of mass spectrometry to predict stability of compounds in physiological conditions
may become an important tool.
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